December 16, 2014
Andrew P. Schachat, MD
A treat-and-extend protocol improved vision and reduced retinal thickness for up to 3 years in patients with neovascular age-related macular degeneration, according to study findings.
The retrospective study included 212 eyes of 189 patients with treatment-naïve neovascular AMD treated with Lucentis 0.5 mg/0.05 mL (ranibizumab, Genentech) or Avastin 1.25 mg/0.05 mL (bevacizumab, Genentech) for at least 1 year under a treat-and-extend regimen.
December 15, 2014
A 12-year-old girl was referred to the New England Eye Center by an outside ophthalmologist for evaluation of decreased vision in both eyes.She was first noticed to have…
December 12, 2014
Floaters are one of the most common presenting complaints in our retina clinics and perhaps in ophthalmology in general. Floaters not associated with retinal pathology…
In the Journals
December 11, 2014
Patients treated with a combination systemic and intravitreal antiviral therapy for acute retinal necrosis may be more likely to have an improvement in visual acuity…